Drugs / tetanus toxoid helper peptide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00404339 | Sep 2005 → Mar 2011 | head and neck cancer | Robert Ferris | Completed | No outcome recorded |
| Phase 1 | NCT00118313 | Nov 2004 → Jul 2006 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00118274 | Mar 2005 → Feb 2010 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00705640 Background | May 2008 → Jun 2009 | conjunctival cancer, cutaneous melanoma, ocular melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1 | NCT00091273 Background | Jun 2004 → Feb 2006 | ovarian cancer, primary peritoneal carcinoma | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00373217 Background | Apr 2006 → Feb 2008 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Craig L Slingluff, Jr | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tetanus toxoid helper peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00404339 ↗ |
| Known as | TET | “multi-epitope melanoma peptides (MP), tetanus toxoid helper peptide (TET), and sargramostim (GM-CSF)” NCT00118313 ↗ |
| Modality | Peptide | “tetanus toxoid helper peptide” NCT00091273 ↗ |
| Route | Other | “subcutaneously and intradermally” NCT00091273 ↗ |
| Route | Subcutaneous | “subcutaneously and intradermally” NCT00091273 ↗ |